Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABCL AbCellera Biologics	$2.01 -1.0%	$2.35	$1.89 ▼ $4.34	$599.83M	0.46	2.73 million shs	3.23 million shs
ABUS Arbutus Biopharma	$3.28 -1.4%	$3.29	$2.71 ▼ $4.73	$627.10M	1.5	996,503 shs	1.11 million shs
KALV KalVista Pharmaceuticals	$12.25 -1.9%	$11.99	$7.30 ▼ $15.50	$609.02M	0.05	414,232 shs	491,325 shs
NBTX Nanobiotix	$3.34 -1.6%	$3.38	$2.76 ▼ $7.51	$157.19M	0.26	15,129 shs	23,788 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABCL AbCellera Biologics	-7.53%	-20.59%	-3.11%	-40.09%	-50.73%
ABUS Arbutus Biopharma	-4.99%	-2.20%	+3.25%	-7.10%	+19.11%
KALV KalVista Pharmaceuticals	-4.70%	-4.56%	+16.56%	+26.10%	+2.83%
NBTX Nanobiotix	-0.81%	+10.44%	+8.41%	+3.35%	-43.91%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABCL AbCellera Biologics	2.145 of 5 stars	3.3	1.0	0.0	2.1	3.3	0.6
ABUS Arbutus Biopharma	2.2787 of 5 stars	3.5	0.0	0.0	3.9	2.5	0.6
KALV KalVista Pharmaceuticals	3.9453 of 5 stars	3.6	0.0	4.4	3.7	2.5	0.6
NBTX Nanobiotix	1.4435 of 5 stars	3.3	3.0	0.0	1.0	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABCL AbCellera Biologics	2.67	Moderate Buy	$7.50	273.13% Upside
ABUS Arbutus Biopharma	3.00	Buy	$5.50	67.94% Upside
KALV KalVista Pharmaceuticals	3.13	Buy	$24.83	102.72% Upside
NBTX Nanobiotix	2.50	Moderate Buy	$8.00	139.88% Upside

Current Analyst Ratings Breakdown

Latest NBTX, ABUS, ABCL, and KALV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/16/2025	ABCL AbCellera Biologics	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$4.00 ➝ $5.00
4/8/2025	KALV KalVista Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00 ➝ $28.00
4/4/2025	NBTX Nanobiotix	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $8.00
3/28/2025	ABUS Arbutus Biopharma	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
3/26/2025	KALV KalVista Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00 ➝ $28.00
3/26/2025	KALV KalVista Pharmaceuticals	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
3/14/2025	KALV KalVista Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
3/13/2025	KALV KalVista Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00 ➝ $28.00
3/3/2025	ABCL AbCellera Biologics	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
2/28/2025	ABCL AbCellera Biologics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $10.00
2/17/2025	NBTX Nanobiotix	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold

(Data available from 5/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABCL AbCellera Biologics	$28.83M	20.80	N/A	N/A	$3.97 per share	0.51
ABUS Arbutus Biopharma	$6.17M	101.62	N/A	N/A	$0.63 per share	5.20
KALV KalVista Pharmaceuticals	N/A	N/A	N/A	N/A	$4.86 per share	N/A
NBTX Nanobiotix	-$11.61M	-13.54	N/A	N/A	($0.04) per share	-83.38

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABCL AbCellera Biologics	-$146.40M	-$0.55	N/A	N/A	N/A	-533.32%	-15.73%	-12.22%	5/8/2025 (Estimated)
ABUS Arbutus Biopharma	-$72.85M	-$0.38	N/A	N/A	N/A	-1,137.65%	-68.18%	-51.55%	N/A
KALV KalVista Pharmaceuticals	-$126.64M	-$3.72	N/A	N/A	N/A	N/A	-103.92%	-88.06%	7/10/2025 (Estimated)
NBTX Nanobiotix	-$42.97M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	5/20/2025 (Estimated)

Latest NBTX, ABUS, ABCL, and KALV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/8/2025	Q1 2025	ABCL AbCellera Biologics	-$0.17	N/A	N/A	N/A	$7.12 million	N/A
3/27/2025	Q4 2024	ABUS Arbutus Biopharma	-$0.08	-$0.07	+$0.01	-$0.07	$2.20 million	$1.57 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABCL AbCellera Biologics	N/A	N/A	N/A	N/A	N/A
ABUS Arbutus Biopharma	N/A	N/A	N/A	N/A	N/A
KALV KalVista Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NBTX Nanobiotix	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABCL AbCellera Biologics	N/A	9.34	9.34
ABUS Arbutus Biopharma	N/A	7.02	7.02
KALV KalVista Pharmaceuticals	N/A	6.87	6.87
NBTX Nanobiotix	N/A	1.42	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABCL AbCellera Biologics	61.42%
ABUS Arbutus Biopharma	43.79%
KALV KalVista Pharmaceuticals	N/A
NBTX Nanobiotix	38.81%

Insider Ownership

Company	Insider Ownership
ABCL AbCellera Biologics	28.00%
ABUS Arbutus Biopharma	20.30%
KALV KalVista Pharmaceuticals	10.50%
NBTX Nanobiotix	3.45%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABCL AbCellera Biologics	500	298.42 million	212.66 million	Optionable
ABUS Arbutus Biopharma	90	191.48 million	181.91 million	Optionable
KALV KalVista Pharmaceuticals	100	49.72 million	44.23 million	Optionable
NBTX Nanobiotix	100	47.13 million	45.51 million	Not Optionable

NBTX, ABUS, ABCL, and KALV Headlines

Recent News About These Companies

Nanobiotix Reveals Favorable Results Of JNJ-1900 Study Pancreatic Cancer; Seeks Further Evaluation

May 5 at 8:31 AM | finanznachrichten.de

Nanobiotix Announces Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer

May 5 at 2:00 AM | globenewswire.com

Nanobiotix Announces Presentation of Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer Followed by a Conference Call

April 30, 2025 | globenewswire.com

Nanobiotix (NBTX) Expected to Announce Quarterly Earnings on Wednesday

April 17, 2025 | marketbeat.com

Nanobiotix price target lowered to $8 from $12 at Guggenheim

April 5, 2025 | markets.businessinsider.com

Nanobiotix (NBTX) Gets a Hold from UBS

April 5, 2025 | markets.businessinsider.com

Nanobiotix S.A. (NBTX) Q4 2024 Earnings Call Transcript

April 3, 2025 | seekingalpha.com

NANOBIOTIX Provides Business Update and Reports Full Year 2024 Financial Results

April 2, 2025 | globenewswire.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Pfizer (PFE), Nanobiotix (NBTX) and PTC Therapeutics (PTCT)

April 2, 2025 | theglobeandmail.com

NANOBIOTIX to Announce Fourth Quarter and Full Year 2024 Operational and Financial Update on April 2, 2025

March 31, 2025 | globenewswire.com

Nanobiotix reports promising NSCLC treatment study results

March 29, 2025 | investing.com

Nanobiotix Announces First Data From the Completed Dose Escalation Part of a Phase 1 Study Evaluating NBTXR3 (JNJ-1900) as a 2L+ Therapy for Patients With Locally Advanced NSCLC

March 27, 2025 | globenewswire.com

NANOBIOTIX Announces Presentation of Data From Two Phase 1 Studies Evaluating JNJ-1900 (NBTXR3)

March 21, 2025 | djournal.com

NANOBIOTIX Announces Presentation of Data From Two Phase 1 Studies Evaluating JNJ-1900 (NBTXR3) at the European Lung Cancer Conference

March 20, 2025 | globenewswire.com

Nanobiotix amends global licensing agreement with Janssen Pharmaceutica

March 18, 2025 | markets.businessinsider.com

NANOBIOTIX Strengthens Financial Position Through Amendment of Global Licensing Agreement for JNJ-1900 (NBTXR3) and Extends Cash Visibility to Mid-2026

March 17, 2025 | globenewswire.com

Nanobiotix files $200M mixed securities shelf

March 7, 2025 | markets.businessinsider.com

Nanobiotix files to sell 5.62M ordinary shares for holders

March 7, 2025 | markets.businessinsider.com

Nanobiotix downgraded to Neutral from Buy at UBS

February 17, 2025 | markets.businessinsider.com

UBS downgrades Nanobiotix (NBTX) to a Hold

February 17, 2025 | markets.businessinsider.com

7 Best Nanotech Penny Stocks to Invest In

February 14, 2025 | insidermonkey.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NBTX, ABUS, ABCL, and KALV Company Descriptions

AbCellera Biologics NASDAQ:ABCL

$2.01 -0.02 (-0.99%)

Closing price 04:00 PM Eastern

Extended Trading

$2.06 +0.05 (+2.24%)

As of 07:56 PM Eastern

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Arbutus Biopharma NASDAQ:ABUS

$3.28 -0.05 (-1.36%)

Closing price 03:59 PM Eastern

Extended Trading

$3.28 +0.01 (+0.31%)

As of 07:59 PM Eastern

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

KalVista Pharmaceuticals NASDAQ:KALV

$12.25 -0.24 (-1.92%)

Closing price 04:00 PM Eastern

Extended Trading

$12.24 -0.01 (-0.04%)

As of 05:24 PM Eastern

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.

Nanobiotix NASDAQ:NBTX

$3.34 -0.06 (-1.62%)

As of 03:38 PM Eastern

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time